Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
'Stealth' corporate innovation: an emerging threat for therapeutic drug development.
Mastellos DC, Blom AM, Connolly ES, Daha MR, Geisbrecht BV, Ghebrehiwet B, Gros P, Hajishengallis G, Holers VM, Huber-Lang M, Kinoshita T, Mollnes TE, Montgomery RA, Morgan BP, Nilsson B, Pio R, Ricklin D, Risitano AM, Taylor RP, Mantovani A, Ioannidis JPA, Lambris JD. Mastellos DC, et al. Among authors: pio r. Nat Immunol. 2019 Nov;20(11):1409-1413. doi: 10.1038/s41590-019-0503-1. Nat Immunol. 2019. PMID: 31562490 Free PMC article.
Complement inhibition in cancer therapy.
Pio R, Ajona D, Lambris JD. Pio R, et al. Semin Immunol. 2013 Feb;25(1):54-64. doi: 10.1016/j.smim.2013.04.001. Epub 2013 May 24. Semin Immunol. 2013. PMID: 23706991 Free PMC article. Review.
The role of complement in tumor growth.
Pio R, Corrales L, Lambris JD. Pio R, et al. Adv Exp Med Biol. 2014;772:229-62. doi: 10.1007/978-1-4614-5915-6_11. Adv Exp Med Biol. 2014. PMID: 24272362 Free PMC article. Review.
Complement C4d-specific antibodies for the diagnosis of lung cancer.
Ajona D, Okrój M, Pajares MJ, Agorreta J, Lozano MD, Zulueta JJ, Verri C, Roz L, Sozzi G, Pastorino U, Massion PP, Montuenga LM, Blom AM, Pio R. Ajona D, et al. Among authors: pio r. Oncotarget. 2017 Dec 26;9(5):6346-6355. doi: 10.18632/oncotarget.23690. eCollection 2018 Jan 19. Oncotarget. 2017. PMID: 29464077 Free PMC article.
Complementing the Cancer-Immunity Cycle.
Pio R, Ajona D, Ortiz-Espinosa S, Mantovani A, Lambris JD. Pio R, et al. Front Immunol. 2019 Apr 12;10:774. doi: 10.3389/fimmu.2019.00774. eCollection 2019. Front Immunol. 2019. PMID: 31031765 Free PMC article. Review.
Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug development.
Mastellos DC, Blom AM, Connolly ES, Daha MR, Geisbrecht BV, Ghebrehiwet B, Gros P, Hajishengallis G, Holers VM, Huber-Lang M, Kinoshita T, Mollnes TE, Montgomery RA, Morgan BP, Nilsson B, Pio R, Ricklin D, Risitano AM, Taylor RP, Mantovani A, Ioannidis JPA, Lambris JD. Mastellos DC, et al. Among authors: pio r. Nat Immunol. 2019 Nov;20(11):1556. doi: 10.1038/s41590-019-0531-x. Nat Immunol. 2019. PMID: 31605100
Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis.
Ortiz-Espinosa S, Morales X, Senent Y, Alignani D, Tavira B, Macaya I, Ruiz B, Moreno H, Remírez A, Sainz C, Rodriguez-Pena A, Oyarbide A, Ariz M, Andueza MP, Valencia K, Teijeira A, Hoehlig K, Vater A, Rolfe B, Woodruff TM, Lopez-Picazo JM, Vicent S, Kochan G, Escors D, Gil-Bazo I, Perez-Gracia JL, Montuenga LM, Lambris JD, Ortiz de Solorzano C, Lecanda F, Ajona D, Pio R. Ortiz-Espinosa S, et al. Among authors: pio r. Cancer Lett. 2022 Mar 31;529:70-84. doi: 10.1016/j.canlet.2021.12.027. Epub 2021 Dec 28. Cancer Lett. 2022. PMID: 34971753
155 results